SecBot SecBot
Insider Cluster (2 insiders) ·Filed Sep 18, 2026

CBIO

CRESCENT BIOPHARMA, INC.
NEUTRAL
Impact 3/10
Horizondays Processed1mo ago
Insider cluster: 2 insiders, $195K total
Actionable Insight • Neutral

The dollar amount is too small to signal material non-public information. Monitor for any 10b5-1 plan disclosures or subsequent Form 4 filings that might reveal a pattern. If the company announces a catalyst (e.g., trial data, partnership) in the next 30 days, these sales could be re-evaluated as opportunistic, but currently they appear routine.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d
CBIO ▼ -23.94% at T+20d
NEUTRAL call -23.94% · α vs SPY -23.03% · entry $16.25 → $12.36
Next anchor: T+60d in 7w
Latest observation: T+24 -16.74% FF3 residual α
Entry = T+0 close
Sep 21, 2026
via day close
T+1d
+1.17%
call +1.17% · α +1.18%
$16.44
settled 5w ago
T+5d
-10.58%
call -10.58% · α -9.56%
$14.53
settled 29d ago
T+20d
-23.94%
call -23.94% · α -23.03%
$12.36
settled 8d ago
T+60d
Pending
in 7w

Price Chart

Loading chart...

Executive Summary

CEO Joshua Brumm and President/COO Jonathan McNeill sold a combined $195K of CBIO stock on September 18, 2026, at $16.71 per share. The sales are open-market (code S) but represent only ~0.06% of the company's ~$326M market cap — well below the 0.1% materiality threshold — and both executives sold on the same day, suggesting a routine liquidity event (e.g., tax planning or 10b5-1 plan) rather than a coordinated bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$195.0K
Insiders
2

Key Facts

  • CEO Joshua Brumm sold 7,800 shares for $131K on September 18, 2026.
  • President/COO Jonathan McNeill sold 3,800 shares for $64K on September 18, 2026.
  • Total insider sales of $195K represent ~0.06% of market cap — trivial.
  • Both sales occurred on the same day at the same price ($16.71), consistent with a pre-arranged plan or tax-related sale.
  • No open-market purchases in the cluster; no C-suite buying to offset the sales.

Financial Impact

Total insider sales of $195K, representing ~0.06% of market cap — immaterial.

insider ownership

Risk Factors

  • If both executives continue selling in similar amounts over the next 60 days, the pattern could become more informative.
  • No insider buying to offset the sales — a sustained selling trend would be bearish.

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CBIO-1789797751617
16 reports for CBIO
Performance horizon
75% Hit rate @ T+60 3 of 4 directional calls Went positive at some point 4 of 4 best @ T+60▲ +9.89%Jul 14, 2026
Filters
Rows
Reports for CBIO — sortable, filterable
TypeNow
Oct 15, 2026
11d ago
8-K
NEUTRAL ★ 3/10
$11.84awaiting T+60—$12.76 (+7.77%)
Oct 15, 2026
11d ago
Press Release
NEUTRAL ★ 4/10
$11.84awaiting T+60—$12.76 (+7.77%)
Oct 5, 2026
21d ago
Press Release
NEUTRAL ★ 4/10
$13.94awaiting T+60—$12.76 (−8.46%)
Sep 18, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$16.25awaiting T+60—$12.76 (−21.48%)
Jul 30, 2026
12w ago
8-K
NEUTRAL ★ 3/10
$15.02 $12.82▼ −14.65%▼ −17.11%$12.76 (−15.05%)
Jul 20, 2026
14w ago
Insider Buy
BULLISH ★ 7/10
$16.64 $12.91▼ −22.42%▼ −26.39%$12.76 (−23.32%)
Jul 15, 2026
14w ago
8-K / 424B5
BEARISH ★ 6/10
$15.11 $14.91▲ +1.32%▲ +5.03%$12.76 (+15.55%)
Jul 14, 2026
14w ago
Press Release
BEARISH ★ 7/10
$15.67 $14.12▲ +9.89%▲ +12.42%$12.76 (+18.57%)
Jul 14, 2026
14w ago
424B5
BEARISH ★ 6/10
$15.67 $14.12▲ +9.89%▲ +12.42%$12.76 (+18.57%)
Jul 13, 2026
15w ago
EFFECT
NEUTRAL ★ 3/10
$15.69 $13.57▼ −13.51%▼ −17.51%$12.76 (−18.67%)
Showing 10 of 16

US Market Status

Market Closed — Opens in 3h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 18, 2026